# US 2023/0405106 A1 · Chimeric protein comprising the receptor binding domain of the corona virus spike protein and compositions comprising them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0405106 A1
- Document ID: US20230405106A1
- Status: Published application
- Kind: A1
- Application number: 18/035,254
- Filed: 2021-11-03
- Published: 2023-12-21
- Earliest claimed: 2020-11-04
- Assignees: Centro de Ingenieria Genetica y Biotecnologia
- Applicants: Centro De IngenieríA GenéTica Y BiotecnologíA
- Inventors: Glay CHINEA SANTIAGO; Alejandro Miguel MARTÍN DUNN; Diamilé GONZÁLEZ ROCHE; Miladys LIMONTA FERNÁNDEZ; Enrique IGLESIAS PÉREZ; Mónica BEQUET ROMERO; Héctor SANTANA MILIAN; Gabriel J. MARQUEZ PERERA; Alexis MUSACCHIO LASA; Ania CABRALES RICO; Gerardo Enrique GUILLEN NIETO; Marta AYALA ÁVILA; Eulogio PIMENTEL VAZQUEZ; Gertrudis ROJAS DORANTES; Vivian HUERTA GALINDO
- Web page: https://patentgrep.com/patent/US20230405106A1

## CPC

- A61K 39/12: Viral antigens
- A61P 31/14: for RNA viruses
- C07K 14/005: from viruses
- A61K 2039/6075: {Viral proteins}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/21: containing a His-tag
- C07K 2319/735: containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20071: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides a chimeric protein that has a modular structure and comprises a receptor binding domain (RBD) from the spike protein (S) of coronaviruses, a segment able to bind the core antigen from the Hepatitis B Virus (HBcAg), a segment including six consecutive histidine residues (HHHHHH), and two spacer segments. In this chimeric protein the aforementioned segments are arranged in a specific order, and the protein is able to form hybrid nanoparticles with HBcAg. The chimeric protein is part of vaccine compositions used for the prevention of coronavirus infections. Therefore, the invention discloses a method for the prevention of coronavirus infections, whereby a vaccine composition comprising said chimeric protein is administered.

## Claims

### Claim 1

A chimeric protein having a modular structure, comprising:
a) A receptor-binding domain (RBD) from the coronavirus Spike protein (S) that comprises a segment of said domain from protein S.
b) A segment able to bind the nucleocapsid antigen of the Hepatitis B Virus (HBcAg) that comprises the amino acid sequence WSFFSNI.
c) A segment that comprises the amino acid sequence HHHHHH.
d) A flexible 5-12 amino acids spacer segment formed by the amino acids G and S.
e) A 7-20 amino acids spacer segment that is selected between a segment that comprises SSSSSSSSSS and the segment STNLAAA,
wherein segments from (a) to (e) are arranged in (b)-(d)-(a)-(e)-(c) order or in (c)-(e)-(a)-(d)-(b) order.

### Claim 2 (depends on 1)

The chimeric protein according to claim 1 wherein the RBD segment (a) is a segment that is located between amino acids Q320 and C590 of protein S from SARS-CoV-2.

### Claim 3 (depends on 1)

The chimeric protein according to claim 1 wherein the flexible 5-12 amino acids spacer segment (d) has an amino acid sequence selected from the group composed of sequences GGSGG, GGSSGGS, GGGSSGGG, GGGSSGGSSGGG and GGSGGSGGS.

### Claim 4 (depends on 1)

The chimeric protein according to claim 1 wherein the 7-20 amino acids spacer segment (e) has an amino acid sequence selected from the group composed of sequences GGSGGSSSSSSSSSSIE, SSGSSSSSSSSSS and GGSGGSSSSSSSSSSGGGIE.

### Claim 5 (depends on 1)

The chimeric protein according to claim 1, having the amino acid sequence identified as SEQ ID NO: 4 or SEQ ID NO: 5.

### Claim 6 (depends on 1)

A vaccine composition comprising the chimeric protein according to claim 1 and pharmaceutically acceptable excipients or diluents.

### Claim 7 (depends on 6)

The vaccine composition according to claim 6 containing additionally a vaccine adjuvant.

### Claim 8 (depends on 7)

The vaccine composition according to claim 7 wherein the vaccine adjuvant is an aluminum salt.

### Claim 9 (depends on 6)

The vaccine composition according to claim 6 containing additionally the nucleocapsid antigen from the Hepatitis B Virus (HBcAg).

### Claim 10 (depends on 9)

The vaccine composition according to claim 9 wherein the chimeric protein and HBcAg are forming hybrid nanoparticles.

### Claim 11 (depends on 6)

The vaccine composition according to claim 6 containing additionally a second coronavirus antigen.

### Claim 12 (depends on 6)

The vaccine composition according to claim 6 administered through the parenteral route, the mucosal route, or a combination thereof.

### Claim 13 (depends on 6)

The vaccine composition according to claim 6 wherein the chimeric protein is selected from the amino acid sequences consisting of SEQ ID NO: 4 or SEQ ID NO: 5.

### Claim at position 14

-17. (canceled)

### Claim 18 (depends on 1)

A method to prevent an infection caused by a coronavirus, said method comprising administering to an affected individual a pharmaceutically effective amount of a vaccine composition comprising the chimeric protein from claim 1 and pharmaceutically acceptable excipients or diluents.

### Claim 19 (depends on 18)

The prevention method according to claim 18 wherein the vaccine composition further comprises a nucleocapsid antigen from the Hepatitis B Virus (HBcAg).

### Claim 20 (depends on 18)

The prevention method according to claim 18 wherein the vaccine composition is administered through the parenteral route, the mucosal route, or a combination thereof.
